Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study

Obesity Science and Practice

Volumn 4, Issue 5, 2018, Pages 477-482

  Itani, Toshio ^a   Ishihara, Tomoaki ^b  

^a Asahi Clinic   (Japan)

^b Yokkaichi Digestive Disease Center   (Japan)

Author keywords

canagliflozin; NAFLD; SGLT2 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANAGLIFLOZIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT LOSS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FERRITIN BLOOD LEVEL; FIBROSIS 4 INDEX; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 85057743699     PISSN: None     EISSN: 20552238     Source Type: Journal    
DOI: 10.1002/osp4.294     Document Type: Article

References (30)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221–1231.
2. Beaton MD, Chakrabarti S, Adams PC. Inflammation is not the cause of an elevated serum ferritin in non-alcoholic liver disease. Ann Hepatol. 2014; 13: 353–356.
3. Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016; 65: 1183–1195.
4. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009; 8: S40–S43.
5. Nagano S, Katsuo K, Isaji M, et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol. 2015; 5: 190–198.
6. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016; 42: 25–32.
7. Katsuyama H, Hasasaki H, Adachi H, et al. Effects of sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 diabetes: a chart-based analysis. J Clin Med Res. 2016; 8: 237–243.
8. Scheen AJ. Pharmacokinetics, phamacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015; 54: 691–708.
9. Vallet-Pichhard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007; 46: 32–36.
10. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708–2715.
11. Sun YN, Zhou Y, Chen X, Che WS, Leung SW. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomized controlled trials. BMJ Open. 2014; 4: e004619.
12. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2: e001007.
13. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med. 2013; 159: 262–274.
14. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014; 35: 391–404.
15. Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015; 7: 104.
16. Harris EH. Elevated liver function tests in type 2 diabetes. Clin Diabetes. 2005; 23: 115–119.
17. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103–107.
18. Vilar-Gonez E, Matinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149: 367–378.
19. Khodadoostan M, Zammanidoost M, Shavakhi A, et al. Effects of phlebotomy on liver enzyme and histology of patients with nonalcoholic fatty liver disease. Adv Biomed Res. 2017; 6: 12.
20. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413–419.
21. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55: 77–85.
22. Penkowa M, Dragnerva S, Marinova C, et al. Phlebotomy in the treatment of iron overload in patients with nonalcoholic and alcoholic fatty liver diseases. Int J Bus Hum Tech. 2012; 2: 48–51.
23. Barros RK, Cotrim HP, Daltro CH, Oliveira YA. Hyperferritinemia in patients with nonalcoholic fatty liver disease. Rev Assoc Med Bras. 2017; 63: 284–289.
24. Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatitis. Redox Rep. 2013; 18: 127–133.
25. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008; 103: 1372–1379.
26. Estrep JM, Baranowa A, Hossain N, et al. Expression of cytokine signaling genes in morbidly obese patients with nonalcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009; 19: 617–624.
27. Syn WK, Choi SS, Diehl AM, et al. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis. 2009; 13: 565–580.
28. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013; 9: 114–118.
29. Wang Y, Zhou M, Lam KS, et al. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol. 2009; 53: 201–212.
30. Nones RB, Ivantes CP, Pedroso MLA. Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic liver disease to a hepatologist? Arch Endocrinol Metab. 2017; 61: 276–281.